FDA 483 - Sichuan Qingmu Pharmaceutical Co., Ltd - October 24, 2025

An FDA inspection of Sichuan Qingmu Pharmaceutical Co. Ltd., an API manufacturer in Meishan City, China, from October 20-24, 2025, identified one observation. The firm was cited for not maintaining adequate records associated with the receiving of raw materials, specifically lacking a chronological and sequential receiving log. This indicates a deficiency in their paper-based material management system.